Biopharma investors set plans for expedited ROI by developing products, not companies
This article was originally published in Scrip
Executive Summary
If the biotechnology industry initially embraced a credo of "The Little Engine that Could" – the story of a little railroad engine with 'can-do' attitude - a more relevant description of the last 10 years may be "Little Big Pharma," according to a recent meeting of a group of investors and executives.